Veru Inc. (NASDAQ: VERU) – Stock Movement and Analyst Coverage Update
Veru Inc. (NASDAQ: VERU) reported a trading session on 30 December 2025 in which the company’s share price fell below its 200‑day moving average. The 200‑day moving average for VERU is $3.88; the stock dipped to a low of $2.15 and closed the day at $2.21. Trading volume for the session was 221,361 shares.
Technical Analysis
- 200‑Day Moving Average: $3.88
- Lowest Price During Session: $2.15
- Closing Price: $2.21
The breach of the 200‑day moving average is generally considered a bearish signal for short‑term investors, prompting discussions among market participants about whether to sell the shares.
Analyst Coverage
Several research houses have issued coverage reports on VERU in the past month:
| Analyst / Firm | Rating | Price Target | Coverage Start Date | Comments |
|---|---|---|---|---|
| Wall Street Zen | Hold (upgraded from Sell) | – | 20 December 2025 | Upgrade reflects a change in view but retains caution. |
| Canaccord Genuity | Buy | $25.00 | 18 December 2025 | New coverage with an optimistic price objective. |
| Oppenheimer | Outperform | – | 18 December 2025 | Maintains an upbeat stance on the stock. |
| Weiss Ratings | Sell (e+) | – | 8 October 2025 | Continues a negative outlook. |
Out of four analysts, three have issued a Buy or Outperform rating, while one maintains a Sell rating. The consensus reflects mixed confidence in VERU’s near‑term prospects.
Company Profile
- Sector: Health Care
- Industry: Personal Care Products (biopharmaceutical focus)
- Headquarters: Miami, Florida
- Primary Exchange: Nasdaq (USD)
- Market Capitalization: $34.83 million
- P/E Ratio: –2.03 (negative earnings)
- Recent Share Price: $2.14 (30 December 2025)
Veru’s product pipeline centers on medications for prostate cancer treatment and supportive care, as well as urology specialty pharmaceuticals. The company’s financials show a low 52‑week range ($2.10 – $14.20) and a recent close near the bottom of that range.
Market Context
The stock’s technical breach and mixed analyst coverage may influence short‑term trading activity. Investors should consider the company’s negative earnings, the significant gap between the current price and the 200‑day moving average, and the divergent analyst views when forming investment decisions.